Accelerating Bioproduction Through Automation, Data Intelligence, and Precision Engineering. Escherichia coli remains the indispensable workhorse for recombinant protein expression and metabolic engineering. However, the path from a wild-type sequence to an industrial-strength producer requires sophisticated selection and engineering strategies. CD Biosynsis provides professional E. coli Strain Development and Screening Services, integrating High-Throughput Screening (HTS), Adaptive Laboratory Evolution (ALE) data, and Precision Genome Editing to deliver optimized "chassis" strains tailored for enzymes, complex proteins, and high-value metabolites.
Get a Technical QuoteWe offer a multidimensional approach to strain engineering, moving beyond simple transformation to systematic genomic optimization and automated phenotypic evaluation. Our platform is designed to identify high-performing clones with industrial-grade stability.
| Service Tier | Technical Strategy | Best For | Standard Deliverables |
|---|---|---|---|
| HTS & Automation | 96-well Micro-fermentation | Rapid selection of high-yield clones | Top clones ID + Growth/Titer profiles |
| Metabolic Chassis Design | Targeted Multi-gene Knockouts | Eliminating byproduct competition | Engineered "blank" chassis strains |
| Adaptive Evolution | Data-driven ALE Benchmarking | Improving stress tolerance (pH, salt) | Evolved strains + Mutational analysis |
| Functional Library Screen | Keio Collection & NBRP Tools | Identifying key functional genes | Gene-phenotype mapping report |
1. Consultation & Design
2. Genomic Engineering
3. High-Throughput Screening
4. Validation & Scale-up
Target evaluation and selection of the optimal base host (e.g., K-12 BW25113, BL21, or specialized iVEC strains for seamless cloning).
Formal project proposal and Mutual NDA signing.
Application of CRISPR or Lambda-Red recombineering for gene knockouts, insertions, or complete metabolic pathway reconstruction.
Standardized genomic integration for long-term genetic stability.
Automated evaluation of large clone libraries under varying induction conditions to identify superior producers.
Real-time monitoring of growth and titer in micro-scale bioreactors.
Verification of genetic stability and performance assessment in pilot-scale bioreactors.
Final delivery of optimized chassis strains and genetic characterization reports.
To deliver world-class results, our technical team continuously monitors and benchmarks our protocols against landmark research in the field. Please note that these studies represent established academic and industrial benchmarks and were not conducted by our company.
This report details how CDMOs (Contract Development and Manufacturing Organizations) such as KBI Biopharma utilize high-throughput screening (HTS) and automated micro-fermentation platforms to accelerate strain development. By using 96-well plates or droplet technology, researchers can rapidly evaluate strain growth rates and product generation capabilities under small-volume conditions. The automation system integrates liquid-handling robots, significantly reducing the variability and time costs associated with manual operations. This is particularly critical when screening for recombinant proteins that are difficult to fold or require disulfide bonds, such as antigen-binding fragments (Fabs), cytokines, and enzymes.
(Reference: Brian Gazaille with Erik Nordwald, 2023)
This research demonstrates how to utilize Adaptive Laboratory Evolution (ALE) databases for computer-aided strain design. By aggregating large amounts of mutant data, researchers can identify gene mutations that perform exceptionally well in specific environments (such as high salt or acidic pH). Furthermore, metabolic network models are used to predict which gene knockouts or overexpressions can improve the flux of target metabolic pathways. This allows for more targeted gene editing—rather than blind random mutagenesis—and is applicable to both biofuels and high-value pharmaceutical intermediates.
(Reference: Phaneuf, Patrick V. et al., 2021)
This report introduces the Keio Collection and iVEC strain libraries, which are fundamental tools for genome-wide screening and functional analysis. The Keio Collection contains single-gene knockout mutants for 3,985 non-essential genes, providing a unified background strain (E. coli K-12 BW25113) for systematic analysis. Additionally, iVEC strains support seamless cloning, facilitating the rapid construction of recombinant plasmids. Using a unified strain background significantly reduces experimental variability and improves the comparability of screening results, allowing for the rapid identification of key genes related to target product synthesis.
(Reference: MEXT National BioResource Project, 2022)
This study demonstrates the creation of a metabolic "blank" platform for the biosynthesis of non-natural amino acids through specific gene knockouts (such as ΔtrpR, ΔpheA, and ΔtyrA). By knocking out the host's natural metabolic pathways to prevent substrate competition, heterologous pathways expressed by exogenous genes can monopolize resources for target product synthesis. This strategy successfully incorporated halogenated tryptophan derivatives, showcasing the platform's potential in synthesizing complex natural product precursors and its ability to adapt to diverse metabolic engineering needs through simultaneous multi-gene knockouts.
(Reference: Zhang et al., 2021)
1. Why is high-throughput screening (HTS) necessary in strain development?
HTS allows for the parallel testing of thousands of genetic and environmental combinations, ensuring the discovery of rare high-performing clones that traditional low-throughput methods would miss.
2. How do you choose between adaptive evolution and rational design?
Rational design is used for known metabolic targets, while adaptive evolution is ideal for improving complex, multi-genic traits like tolerance to toxic products or extreme environments.
3. Can you develop a strain starting from a specific commercial host?
Yes. We can apply our engineering and screening toolkits to your existing proprietary strains or standard commercial hosts to enhance their industrial productivity.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.